These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1599801)

  • 1. Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha.
    Meadows LM; Lindley C; Ozer H
    Biotherapy; 1992; 4(3):179-87. PubMed ID: 1599801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
    Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
    Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma.
    Creagan ET; Veeder MH; Suman VJ; Burch PA; Maples WJ; Schaefer PL; Pfeifle DM; Dalton RJ; Hatfield AK; Poon MA
    Am J Clin Oncol; 1998 Oct; 21(5):475-8. PubMed ID: 9781603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
    J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
    Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of carmofur and interferon-alpha-2B in advanced gastrointestinal cancer--a phase II pilot study.
    Gröhn P; Helle L; Numminen S; Heinonen E
    Acta Oncol; 1994; 33(6):711-3. PubMed ID: 7946457
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
    Wadler S; Fell S; Haynes H; Katz HJ; Rozenblit A; Kaleya R; Wiernik PH
    Cancer; 1993 Mar; 71(5):1726-30. PubMed ID: 8448736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic study of 5-FU/leucovorin and alpha-interferon in advanced cancer.
    Larsson PA; Glimelius B; Jeppsson B; Jönsson PE; Malmberg M; Gustavsson B; Carlsson G; Svedberg M
    Acta Oncol; 2000; 39(1):59-63. PubMed ID: 10752655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative treatment for advanced gastrointestinal cancer: is response a suitable end-point?
    Jäger E; Bernard H; Knuth A
    Cancer Treat Rev; 1996 Jan; 22 Suppl A():113-5. PubMed ID: 8625335
    [No Abstract]   [Full Text] [Related]  

  • 11. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
    Yee LK; Allegra CJ; Steinberg SM; Grem JL
    J Natl Cancer Inst; 1992 Dec; 84(23):1820-5. PubMed ID: 1433371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress.
    Larkin JM; Gore ME
    Clin Oncol (R Coll Radiol); 2005 Aug; 17(5):319-21. PubMed ID: 16097560
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
    Sparano JA; Lipsitz S; Wadler S; Hansen R; Bushunow PW; Kirkwood J; Flynn PJ; Dutcher JP; Benson AB
    Am J Clin Oncol; 1996 Dec; 19(6):546-51. PubMed ID: 8931668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin].
    Togashi M; Tabata T; Hirakawa K; Ohashi N; Sindoh J; Hirano T; Demura T
    Hinyokika Kiyo; 1996 Jan; 42(1):43-5. PubMed ID: 8686582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
    Rathmell WK; Malkowicz SB; Holroyde C; Luginbuhl W; Vaughn DJ
    Am J Clin Oncol; 2004 Apr; 27(2):109-12. PubMed ID: 15057147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B; Luis R; Jaime M; Franceschi D
    Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Négrier S; Caty A; Lesimple T; Douillard JY; Escudier B; Rossi JF; Viens P; Gomez F
    J Clin Oncol; 2000 Dec; 18(24):4009-15. PubMed ID: 11118461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
    Nishiyama M; Yamamoto W; Park JS; Okamoto R; Hanaoka H; Takano H; Saito N; Matsukawa M; Shirasaka T; Kurihara M
    Clin Cancer Res; 1999 Sep; 5(9):2620-8. PubMed ID: 10499641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
    Allegra CJ
    JAMA; 1995 Jan; 273(3):236-9. PubMed ID: 7807664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.